Polaris Partners

Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on cancer therapeutics. It operates a laboratory dedicated to studying cancer-driving pathways and developing treatments that target and over-activate specific cancer-linked cell signaling, ultimately leading to the death of tumor cells.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, founded in 2019. The company specializes in developing a platform that enhances collaboration among healthcare stakeholders, including patients, providers, and payers. Cohere Health focuses on improving the efficiency and effectiveness of healthcare delivery by simplifying complex processes through technology. Its primary offering is an intelligent prior authorization solution that is configurable to meet the specific needs of different health plans. This solution can be implemented as a fully outsourced utilization management service, utilizing artificial intelligence, machine learning, and real-time analytics to automate the prior authorization process. By doing so, Cohere Health aims to facilitate seamless communication and guide quality care throughout the patient journey, ultimately improving patient outcomes.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Contact Networks offers Enterprise Relationship Management (ERM) software solutions designed to help professional services firms maximize the value of their relationship networks for business development. Their flagship product, ContactNet, is an automated search application that quickly identifies employees with strong relationships to a client or prospect. Based in Boston, MA, Contact Networks was acquired by Thomson Reuters in 2007.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on mitigating healthcare cyber incidents related to patient data theft, addressing a critical need for chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patient health information (PHI). By implementing a proactive risk management approach, the software aims to improve patient care, clinician satisfaction, regulatory compliance, and foster innovation within healthcare organizations.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Folx Health is a telehealth platform established in 2020, based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. The company focuses on creating a medical service marketplace tailored to the needs of queer and trans individuals, offering access to a network of specialized clinicians. Folx Health's services include gender-affirming hormone therapy, sexual health care, fertility testing, and general medical services. The platform emphasizes discreet delivery of at-home kits for medications, labs, and supplies, enabling users to manage their health without the barriers and stigma often found in traditional healthcare settings.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Scholar Rock, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of biologic therapies that selectively target dysregulated growth factors within disease microenvironments. The company's innovative approach focuses on modulating supracellular activation to address serious diseases, including fibrosis, musculoskeletal disorders, immuno-oncology, and autoimmune diseases. Scholar Rock's lead product candidate, SRK-015, is a first-in-class inhibitor designed to target the activation of the growth factor myostatin in skeletal muscle, specifically for the treatment of spinal muscular atrophy. The company is advancing this candidate through clinical development while also leveraging its proprietary platform to create a pipeline of additional product candidates aimed at transforming treatment for various serious conditions, including other neuromuscular disorders, cancer, and anemia.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

OM1, Inc. is a digital health company based in Boston, Massachusetts, that specializes in developing a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform enables hospitals and health systems to fulfill requirements related to patient-reported and clinical outcomes, particularly within value-based care programs and bundle payments. By integrating predictive and prescriptive analytics, OM1's technology helps mitigate risks, lower costs, and enhance the understanding of healthcare outcomes across the care continuum. The company synthesizes and enriches clinical data to provide actionable insights that improve clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014, OM1 leverages a team of scientists, clinical experts, and software engineers to address the complexities of healthcare results.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company leverages soluble guanylate cyclase (sGC) pharmacology to create next-generation sGC stimulators. Its pipeline includes Olinciguat, an orally administered vascular sGC stimulator in Phase II studies for sickle cell disease; Praliciguat, another oral sGC stimulator in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, a CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is exploring liver-targeted and lung-targeted sGC stimulators. The company was incorporated in 2018.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing adeno-associated virus (AAV) vectors for gene therapy applications. Its innovative platform utilizes artificial intelligence, next-generation DNA synthesis, and high-throughput sequencing to design and optimize AAV capsids, which are crucial for delivering therapeutic genes effectively and safely. By leveraging machine learning and quantitative experimentation, Dyno Therapeutics aims to revolutionize the design of gene vectors, focusing on enhancing cell-targeting capabilities. The company's approach seeks to advance the field of gene therapy, making it possible for researchers to access novel AAV vectors that can facilitate more efficient in vivo delivery of new treatments.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, founded in 2019. The company specializes in developing a platform that enhances collaboration among healthcare stakeholders, including patients, providers, and payers. Cohere Health focuses on improving the efficiency and effectiveness of healthcare delivery by simplifying complex processes through technology. Its primary offering is an intelligent prior authorization solution that is configurable to meet the specific needs of different health plans. This solution can be implemented as a fully outsourced utilization management service, utilizing artificial intelligence, machine learning, and real-time analytics to automate the prior authorization process. By doing so, Cohere Health aims to facilitate seamless communication and guide quality care throughout the patient journey, ultimately improving patient outcomes.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on mitigating healthcare cyber incidents related to patient data theft, addressing a critical need for chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patient health information (PHI). By implementing a proactive risk management approach, the software aims to improve patient care, clinician satisfaction, regulatory compliance, and foster innovation within healthcare organizations.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Folx Health is a telehealth platform established in 2020, based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. The company focuses on creating a medical service marketplace tailored to the needs of queer and trans individuals, offering access to a network of specialized clinicians. Folx Health's services include gender-affirming hormone therapy, sexual health care, fertility testing, and general medical services. The platform emphasizes discreet delivery of at-home kits for medications, labs, and supplies, enabling users to manage their health without the barriers and stigma often found in traditional healthcare settings.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing adeno-associated virus (AAV) vectors for gene therapy applications. Its innovative platform utilizes artificial intelligence, next-generation DNA synthesis, and high-throughput sequencing to design and optimize AAV capsids, which are crucial for delivering therapeutic genes effectively and safely. By leveraging machine learning and quantitative experimentation, Dyno Therapeutics aims to revolutionize the design of gene vectors, focusing on enhancing cell-targeting capabilities. The company's approach seeks to advance the field of gene therapy, making it possible for researchers to access novel AAV vectors that can facilitate more efficient in vivo delivery of new treatments.

Folx Health is a telehealth platform established in 2020, based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. The company focuses on creating a medical service marketplace tailored to the needs of queer and trans individuals, offering access to a network of specialized clinicians. Folx Health's services include gender-affirming hormone therapy, sexual health care, fertility testing, and general medical services. The platform emphasizes discreet delivery of at-home kits for medications, labs, and supplies, enabling users to manage their health without the barriers and stigma often found in traditional healthcare settings.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Amagma Therapeutics is a biotechnology company founded in 2019 and based in Waltham, Massachusetts. The company focuses on the discovery and development of antibody therapeutics aimed at addressing inflammatory diseases caused by enzyme hyperactivity. Specifically, Amagma's therapies target overactive extracellular proteases, which lead to tissue damage and contribute to widespread inflammatory responses. By developing these innovative treatments, Amagma aims to enhance therapeutic efficacy while ensuring patient safety in the management of human diseases linked to enzyme dysfunction.

1366 Technologies Inc., established in 2008, specializes in the development, manufacturing, and supply of silicon wafers for solar cell applications. Based in Bedford, Massachusetts, with additional facilities in Shanghai, China, and Mumbai, India, the company produces both 3D direct wafers and conventional silicon solar wafers. Through strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd., 1366 Technologies supplies its products to major players in the solar industry. Its proprietary technology enables the production of silicon wafers directly from molten silicon, resulting in lower costs, reduced energy requirements, and improved uniformity compared to traditional methods. This allows businesses to create more efficient and cost-effective solar cells.

OM1, Inc. is a digital health company based in Boston, Massachusetts, that specializes in developing a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform enables hospitals and health systems to fulfill requirements related to patient-reported and clinical outcomes, particularly within value-based care programs and bundle payments. By integrating predictive and prescriptive analytics, OM1's technology helps mitigate risks, lower costs, and enhance the understanding of healthcare outcomes across the care continuum. The company synthesizes and enriches clinical data to provide actionable insights that improve clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014, OM1 leverages a team of scientists, clinical experts, and software engineers to address the complexities of healthcare results.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company leverages soluble guanylate cyclase (sGC) pharmacology to create next-generation sGC stimulators. Its pipeline includes Olinciguat, an orally administered vascular sGC stimulator in Phase II studies for sickle cell disease; Praliciguat, another oral sGC stimulator in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, a CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is exploring liver-targeted and lung-targeted sGC stimulators. The company was incorporated in 2018.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

Drizly is an online alcohol marketplace that provides a wide selection of beer, wine, and spirits, along with related products such as mixers and garnishes. Founded in 2012 and headquartered in Boston, Massachusetts, the company enables consumers of legal drinking age to conveniently order alcoholic beverages through its platform, benefiting from on-demand delivery and shipping options. Drizly partners with retailers across 235 markets, allowing them to enhance their visibility and reach new customers by bringing their inventory online. This collaboration not only helps retailers diversify their business but also provides valuable market insights to drive sales growth.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

OM1, Inc. is a digital health company based in Boston, Massachusetts, that specializes in developing a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform enables hospitals and health systems to fulfill requirements related to patient-reported and clinical outcomes, particularly within value-based care programs and bundle payments. By integrating predictive and prescriptive analytics, OM1's technology helps mitigate risks, lower costs, and enhance the understanding of healthcare outcomes across the care continuum. The company synthesizes and enriches clinical data to provide actionable insights that improve clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014, OM1 leverages a team of scientists, clinical experts, and software engineers to address the complexities of healthcare results.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Scholar Rock, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of biologic therapies that selectively target dysregulated growth factors within disease microenvironments. The company's innovative approach focuses on modulating supracellular activation to address serious diseases, including fibrosis, musculoskeletal disorders, immuno-oncology, and autoimmune diseases. Scholar Rock's lead product candidate, SRK-015, is a first-in-class inhibitor designed to target the activation of the growth factor myostatin in skeletal muscle, specifically for the treatment of spinal muscular atrophy. The company is advancing this candidate through clinical development while also leveraging its proprietary platform to create a pipeline of additional product candidates aimed at transforming treatment for various serious conditions, including other neuromuscular disorders, cancer, and anemia.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Suono Bio, Inc. is a biotechnology company based in Medford, Massachusetts, that focuses on designing and developing innovative therapeutic products with a unique delivery technology. Established in 2016, the company specializes in enabling ultra-rapid, localized delivery of small molecules, biologics, nucleic acids, and gene therapies directly to the gastrointestinal tract without the need for encapsulation. Suono Bio aims to transform the treatment landscape for difficult-to-treat diseases, particularly those mediated by inflammatory processes, by facilitating effective therapy delivery that enhances patient recovery from gastrointestinal conditions.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Drizly is an online alcohol marketplace that provides a wide selection of beer, wine, and spirits, along with related products such as mixers and garnishes. Founded in 2012 and headquartered in Boston, Massachusetts, the company enables consumers of legal drinking age to conveniently order alcoholic beverages through its platform, benefiting from on-demand delivery and shipping options. Drizly partners with retailers across 235 markets, allowing them to enhance their visibility and reach new customers by bringing their inventory online. This collaboration not only helps retailers diversify their business but also provides valuable market insights to drive sales growth.

Qstream, Inc. is a software company that specializes in developing a mobile sales acceleration platform designed to enhance job proficiency and influence behavior within sales teams. Founded in 2008 and headquartered in Burlington, Massachusetts, Qstream serves clients across various sectors, including technology, financial services, and life sciences. The company operates engineering facilities in Dublin, Ireland, and Hood River, Oregon, while maintaining sales headquarters in Maidenhead, United Kingdom, and an office in San Francisco. Qstream's micro-learning platform enables organizations to manage and measure the human aspects of sales performance, providing analytics-driven insights that facilitate team excellence.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Sofregen Medical Inc. is a biomaterials company based in Medford, Massachusetts, that specializes in developing purified silk protein for aesthetic procedures and surgeries. Founded in 2014, the company is a pioneer in utilizing silk, a natural healing fiber, to address soft tissue defects. Its innovative approach provides plastic surgeons with effective biomaterials, enhancing surgical outcomes and delivering more durable results. Sofregen’s technology is geared towards restoring both function and cosmetic appearance for medical and aesthetic patients, ultimately improving their quality of life and helping to restore their confidence. The company's foundation is rooted in advancements made at Tufts University and the University of Pittsburgh, reflecting its commitment to harnessing scientific innovation in the field of biomaterials.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Boxever Ltd. is a Dublin-based company that specializes in customer intelligence as a service for the travel industry. Founded in 2010, Boxever provides a digital optimization platform that leverages data and artificial intelligence to enhance customer interactions and experiences. Its main offerings include BOXEVER TX, which visualizes the customer journey, and TX-CORE, a traveler experience management solution that helps clients anticipate customer needs. Additionally, the platform features TX-NOW, an offer management tool, and serves as a comprehensive customer data platform (CDP) that integrates information from various online and offline sources. Boxever collaborates with prominent brands such as Emirates and Ryanair, aiming to transform customer engagement through personalized experiences and data-driven decision-making.

Scholar Rock, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of biologic therapies that selectively target dysregulated growth factors within disease microenvironments. The company's innovative approach focuses on modulating supracellular activation to address serious diseases, including fibrosis, musculoskeletal disorders, immuno-oncology, and autoimmune diseases. Scholar Rock's lead product candidate, SRK-015, is a first-in-class inhibitor designed to target the activation of the growth factor myostatin in skeletal muscle, specifically for the treatment of spinal muscular atrophy. The company is advancing this candidate through clinical development while also leveraging its proprietary platform to create a pipeline of additional product candidates aimed at transforming treatment for various serious conditions, including other neuromuscular disorders, cancer, and anemia.

Navitor Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing small molecule drugs that target specific nutrient-sensing proteins to modulate mTORC1 activity. This master regulator of cell growth and metabolism plays a crucial role in various age-related diseases. The company's proprietary platform allows for both selective inhibition and activation of mTORC1, offering potential treatments for conditions such as chronic kidney disease, depression, and other metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases. Notable compounds include NV-5138, which activates mTORC1 and modulates sestrin, a natural activator of mTORC1, and the NValog program, which targets chronic kidney disease through selective mTORC1 inhibition. Founded in 2009, Navitor Pharmaceuticals aims to unlock the therapeutic potential of the mTOR pathway for a wide range of diseases.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, focused on developing innovative inhaled therapies for serious pulmonary diseases. Utilizing its proprietary iSPERSE technology, which stands for inhaled Small Particles Easily Respirable and Emitted, Pulmatrix aims to enhance the delivery of therapeutic agents directly to the lungs while minimizing systemic side effects. The company's product pipeline includes Pulmazole, an inhaled anti-fungal targeting allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor designed for obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD). Established in 2003, Pulmatrix collaborates with various partners, including RespiVert Ltd. and Cipla Technologies LLC, to advance its drug candidates and address significant unmet medical needs in respiratory care.

XTuit Pharmaceuticals, Inc., established in 2011 and headquartered in Waltham, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. The company focuses on creating pharmaceutical preparations for diagnosing and treating oncological, tumor, and inflammatory diseases by pursuing novel approaches that target the tumor microenvironment. Its drug development pipeline and clinical biomarker platform aim to create drugs that inhibit extracellular matrix synthesis and stabilization, and silence activated stromal cells through pleiotropic mechanisms.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, focused on developing innovative polymer-based foams and fibers for the treatment of vascular diseases. Founded in 2005, the company specializes in creating in-situ forming foams designed to deliver local therapy for acute hemorrhage and other critical conditions such as vascular injury and repair. Arsenal Medical has developed two proprietary technology platforms: its therapeutic foam and AxioCore, a novel nanofiber technology that facilitates cell integration and tissue regeneration by enabling controlled delivery of biologics and therapeutics. The company utilizes safe, non-toxic, and biocompatible materials to enhance therapy in complex medical scenarios, positioning itself at the forefront of advancements in local treatment approaches.

Drizly is an online alcohol marketplace that provides a wide selection of beer, wine, and spirits, along with related products such as mixers and garnishes. Founded in 2012 and headquartered in Boston, Massachusetts, the company enables consumers of legal drinking age to conveniently order alcoholic beverages through its platform, benefiting from on-demand delivery and shipping options. Drizly partners with retailers across 235 markets, allowing them to enhance their visibility and reach new customers by bringing their inventory online. This collaboration not only helps retailers diversify their business but also provides valuable market insights to drive sales growth.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

Scholar Rock, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of biologic therapies that selectively target dysregulated growth factors within disease microenvironments. The company's innovative approach focuses on modulating supracellular activation to address serious diseases, including fibrosis, musculoskeletal disorders, immuno-oncology, and autoimmune diseases. Scholar Rock's lead product candidate, SRK-015, is a first-in-class inhibitor designed to target the activation of the growth factor myostatin in skeletal muscle, specifically for the treatment of spinal muscular atrophy. The company is advancing this candidate through clinical development while also leveraging its proprietary platform to create a pipeline of additional product candidates aimed at transforming treatment for various serious conditions, including other neuromuscular disorders, cancer, and anemia.

Navitor Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing small molecule drugs that target specific nutrient-sensing proteins to modulate mTORC1 activity. This master regulator of cell growth and metabolism plays a crucial role in various age-related diseases. The company's proprietary platform allows for both selective inhibition and activation of mTORC1, offering potential treatments for conditions such as chronic kidney disease, depression, and other metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases. Notable compounds include NV-5138, which activates mTORC1 and modulates sestrin, a natural activator of mTORC1, and the NValog program, which targets chronic kidney disease through selective mTORC1 inhibition. Founded in 2009, Navitor Pharmaceuticals aims to unlock the therapeutic potential of the mTOR pathway for a wide range of diseases.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Boxever Ltd. is a Dublin-based company that specializes in customer intelligence as a service for the travel industry. Founded in 2010, Boxever provides a digital optimization platform that leverages data and artificial intelligence to enhance customer interactions and experiences. Its main offerings include BOXEVER TX, which visualizes the customer journey, and TX-CORE, a traveler experience management solution that helps clients anticipate customer needs. Additionally, the platform features TX-NOW, an offer management tool, and serves as a comprehensive customer data platform (CDP) that integrates information from various online and offline sources. Boxever collaborates with prominent brands such as Emirates and Ryanair, aiming to transform customer engagement through personalized experiences and data-driven decision-making.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

GoTo, formerly known as LogMeIn, is a provider of cloud communications and IT solutions, focusing on flexible work software. Its product suite includes GoTo Connect, GoTo Resolve, Rescue, and Central, catering primarily to small and midsize business IT departments while also being suitable for enterprise applications. GoTo's platform facilitates unified communications and collaboration as well as IT management and support, boasting nearly 800,000 customers and enabling over 1 billion participants in various online interactions. The company emphasizes secure, reliable, and AI-enabled solutions that are easy to implement and scale. Headquartered in Boston, Massachusetts, GoTo generates approximately $1 billion in annual revenue and employs around 2,800 individuals across multiple continents.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

1366 Technologies Inc., established in 2008, specializes in the development, manufacturing, and supply of silicon wafers for solar cell applications. Based in Bedford, Massachusetts, with additional facilities in Shanghai, China, and Mumbai, India, the company produces both 3D direct wafers and conventional silicon solar wafers. Through strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd., 1366 Technologies supplies its products to major players in the solar industry. Its proprietary technology enables the production of silicon wafers directly from molten silicon, resulting in lower costs, reduced energy requirements, and improved uniformity compared to traditional methods. This allows businesses to create more efficient and cost-effective solar cells.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

aTyr Pharma, Inc., established in 2005 and headquartered in San Diego, California, is a biotherapeutics company dedicated to discovering and developing innovative medicines based on novel immunological pathways. The company's primary focus is efzofitimod (formerly ATYR1923), a fusion protein currently in clinical trials for treating interstitial lung diseases by modulating immune engagement through the neuropilin-2 receptor. aTyr Pharma has collaborations with academic institutions and industry partners, including the University of Nebraska Medical Center, CSL Behring, Boston Children's Hospital, Kyorin Pharmaceutical Co., Ltd., and the Medical University of South Carolina, to advance its pipeline of immunomodulatory therapeutics derived from tRNA synthetases. The company is backed by prominent life sciences investors such as Alta Partners, Cardinal Partners, Domain Associates, and Polaris Ventures.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS Biomedical's proprietary system is designed to continuously release medications directly into the bladder over extended periods, ranging from weeks to months. This technology is administered through minimally invasive, in-office procedures, allowing for customized drug delivery that aligns with the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapeutics for rare fibrotic diseases and retinal fibrovascular conditions. The company targets conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein designed for intravenous injection, and PRM-167, a variant formulated for intravitreal delivery. Promedior employs a novel drug discovery platform that aims to regulate monocyte-derived cell populations, which are critical in inflammatory, fibrotic, and autoimmune diseases. By specifically addressing these cells at the injury site, Promedior seeks to treat the underlying causes of immune system dysregulation, promote tissue healing, and minimize systemic side effects associated with traditional therapies. The company's commitment to addressing severe and challenging conditions positions it as a significant player in the biopharmaceutical landscape.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

docTrackr is a company that specializes in digital document management, offering businesses solutions to maintain control over their sensitive documents after they have been shared. Its technology allows organizations to remotely manage documents by updating, destroying, and tracking usage in real-time, ensuring complete visibility into how documents are accessed and utilized. The platform features an easy-to-use dashboard that enhances document intelligence and control, complementing existing document management systems such as Dropbox and Google Drive. By providing robust security measures, including document encryption, docTrackr helps enterprises safeguard their information regardless of where it is stored or with whom it is shared. The company has operations in Boston, Paris, and Bucharest, and gained recognition as a participant in a leading startup accelerator before being acquired by Intralinks.com.

WikiCell Designs Inc., a Cambridge, Mass. and Paris, France-based company developing edible forms of food and beverage packaging.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapeutics for rare fibrotic diseases and retinal fibrovascular conditions. The company targets conditions such as myelofibrosis, idiopathic pulmonary fibrosis, age-related macular degeneration, and diabetic retinopathy. Promedior's portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein designed for intravenous injection, and PRM-167, a variant formulated for intravitreal delivery. Promedior employs a novel drug discovery platform that aims to regulate monocyte-derived cell populations, which are critical in inflammatory, fibrotic, and autoimmune diseases. By specifically addressing these cells at the injury site, Promedior seeks to treat the underlying causes of immune system dysregulation, promote tissue healing, and minimize systemic side effects associated with traditional therapies. The company's commitment to addressing severe and challenging conditions positions it as a significant player in the biopharmaceutical landscape.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.